KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma

STOCKHOLM & LONDON--(BUSINESS WIRE)--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions. KKR and Impilo